Nektar Therapeutics Property, Plant and Equipment
Nektar Therapeutics (NKTR) had Property, Plant and Equipment of $2.06 million as of 2025-12-31, per its 10-K filed 2026-03-13.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent › Property, Plant, and Equipment, after Accumulated Depreciation, Depletion, and Amortization
us-gaap:PropertyPlantAndEquipmentNet · last filed 2026-03-13
- 2025-12-31: Property, Plant and Equipment, Net $2.06M.
- 2025-09-30: Property, Plant and Equipment, Net $2.83M.
- 2025-06-30: Property, Plant and Equipment, Net $2.99M.
- 2025-03-31: Property, Plant and Equipment, Net $3.16M.
| Period end | Property, Plant and Equipment, Net | Property, Plant and Equipment, Net as first filed |
|---|---|---|
| 2025-12-31 | $2.06M 10-K · filed 2026-03-13 | |
| 2025-09-30 | $2.83M 10-Q · filed 2025-11-07 | |
| 2025-06-30 | $2.99M 10-Q · filed 2025-08-08 | |
| 2025-03-31 | $3.16M 10-Q · filed 2025-05-09 | |
| 2024-12-31 | $3.41M 10-K · filed 2026-03-13 | |
| 2024-09-30 | $3.60M 10-Q · filed 2024-11-08 | |
| 2024-06-30 | $15.19M 10-Q · filed 2024-08-09 | |
| 2024-03-31 | $17.48M 10-Q · filed 2024-05-10 | |
| 2023-12-31 | $18.86M 10-K · filed 2025-03-14 | |
| 2023-09-30 | $19.95M 10-Q · filed 2023-11-08 | |
| 2023-06-30 | $22.55M 10-Q · filed 2023-08-09 | |
| 2023-03-31 | $27.08M 10-Q · filed 2023-05-10 | |
| 2022-12-31 | $32.45M 10-K · filed 2024-03-05 | |
| 2022-09-30 | $36.80M 10-Q · filed 2022-11-04 | |
| 2022-06-30 | $39.79M 10-Q · filed 2022-08-05 | |
| 2022-03-31 | $60.98M 10-Q · filed 2022-05-06 | |
| 2021-12-31 | $60.51M 10-K · filed 2023-02-28 | |
| 2021-09-30 | $58.83M 10-Q · filed 2021-11-05 | |
| 2021-06-30 | $58.60M 10-Q · filed 2021-08-06 | |
| 2021-03-31 | $58.51M 10-Q · filed 2021-05-07 | |
| 2020-12-31 | $59.66M 10-K · filed 2022-03-01 | |
| 2020-09-30 | $60.19M 10-Q · filed 2020-11-06 | |
| 2020-06-30 | $61.37M 10-Q · filed 2020-08-07 | |
| 2020-03-31 | $62.31M 10-Q · filed 2020-05-08 | |
| 2019-12-31 | $65.67M 10-K · filed 2021-02-26 | $65.00M 10-K · filed 2020-02-28 |
| 2019-09-30 | $64.61M 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $65.45M 10-Q · filed 2019-08-09 | |
| 2019-03-31 | $58.16M 10-Q · filed 2019-05-09 | |
| 2018-12-31 | $48.85M 10-K · filed 2020-02-28 | |
| 2018-09-30 | $44.88M 10-Q · filed 2018-11-08 | |
| 2018-06-30 | $45.00M 10-Q · filed 2018-08-09 | |
| 2018-03-31 | $46.33M 10-Q · filed 2018-05-10 | |
| 2017-12-31 | $47.46M 10-K · filed 2019-03-01 | |
| 2017-09-30 | $62.40M 10-Q · filed 2017-11-08 | |
| 2017-06-30 | $64.93M 10-Q · filed 2017-08-09 | |
| 2017-03-31 | $66.64M 10-Q · filed 2017-05-10 | |
| 2016-12-31 | $65.60M 10-K · filed 2018-03-01 | |
| 2016-09-30 | $65.55M 10-Q · filed 2016-11-04 | |
| 2016-06-30 | $67.77M 10-Q · filed 2016-08-04 | |
| 2016-03-31 | $69.85M 10-Q · filed 2016-05-04 | |
| 2015-12-31 | $71.34M 10-K · filed 2017-03-01 | |
| 2015-09-30 | $72.53M 10-Q · filed 2015-11-06 | |
| 2015-06-30 | $72.16M 10-Q · filed 2015-08-06 | |
| 2015-03-31 | $69.27M 10-Q · filed 2015-05-01 | |
| 2014-12-31 | $70.37M 10-K · filed 2016-02-29 | |
| 2014-09-30 | $69.28M 10-Q · filed 2014-11-07 | |
| 2014-06-30 | $71.07M 10-Q · filed 2014-08-01 | |
| 2014-03-31 | $72.97M 10-Q · filed 2014-05-08 | |
| 2013-12-31 | $66.97M 10-K · filed 2015-02-26 | |
| 2013-09-30 | $65.08M 10-Q · filed 2013-11-07 | |
| 2013-06-30 | $67.85M 10-Q · filed 2013-08-09 | |
| 2013-03-31 | $70.11M 10-Q · filed 2013-05-09 | |
| 2012-12-31 | $72.22M 10-K · filed 2014-02-27 | |
| 2012-09-30 | $73.26M 10-Q · filed 2012-11-09 | |
| 2012-06-30 | $73.71M 10-Q · filed 2012-08-09 | |
| 2012-03-31 | $75.56M 10-Q · filed 2012-05-04 | |
| 2011-12-31 | $78.58M 10-K · filed 2013-03-01 | |
| 2011-09-30 | $81.65M 10-Q · filed 2011-11-04 | |
| 2011-06-30 | $85.38M 10-Q · filed 2011-08-05 | |
| 2011-03-31 | $87.63M 10-Q · filed 2011-04-29 | |
| 2010-12-31 | $89.77M 10-K · filed 2012-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |